CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).

Trial Profile

CHOICES: A Randomized Phase II Trial of Imatinib (IM) Versus Hydroxychloroquine (HCQ) and IM for Patients With Chronic Myeloid Leukemia (CML) in Major Cytogenetic Response (MCyR) With Residual Disease Detectable by Quantitative Polymerase Chain Reaction (Q-PCR).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Imatinib (Primary) ; Hydroxychloroquine
  • Indications Chronic myeloid leukaemia
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CHOICES
  • Most Recent Events

    • 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ISRCTN: Current Controlled Trials record.
    • 15 Jan 2015 Planned End Date changed from 30 Oct 2014 to 19 Dec 2014 as reported by United Kingdom Clinical Research Network record.
    • 15 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top